Real-world data show high efficacy of IL23 inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult-to-treat areas.

Aristeidis G VaiopoulosMaria DalamagaPelagia KatsimbriMarios KoumourtzisKyriaki LampadakiKonstantinos TheodoropoulosSofia TheotokoglouAntonios KanelleasAnna SyrmaliAlexandra FilippopoulouKonstantina ZoupidouAlexander C KatoulisEvangelia Papadavid

Published in: International journal of dermatology (2023)

This real-world study confirms the efficacy and safety of guselkumab and risankizumab in psoriatic arthritis and psoriasis reported from clinical trials.

Keyphrases

clinical trial
electronic health record
big data
randomized controlled trial
machine learning
open label